MSLN is markedly overexpressed in several malignancies, including pancreatic ductal adenocarcinoma (PDAC), ovarian cancer, non-small cell lung cancer (NSCLC), pleural mesothelioma (PM), and others. This evidence concerns the gene MSLN and non-small cell lung carcinoma.